Cipher Pharmaceuticals Inc T.CPH

Alternate Symbol(s): CPHRF

Healthcare

Cipher Pharmaceuticals Inc. is a specialty pharmaceutical company with a diversified portfolio of commercial and early to late-stage products, mainly in dermatology. The Company acquires products that fulfill unmet medical needs, manages the required clinical development and regulatory approval process, and markets those products in Canada, the United States, and South America. Its dermatology products include Actikerall, Epuris, and Vaniqa. Its hospital acute care products include Aggrastat and Brinavess. Its out-licensed products include Absorica, ConZip and Lipofen. Durela is its specialty medicine. Its product pipeline includes MOB-015, CF-101, and DTR-001. It delivers novel products to healthcare professionals and patients in Canada in a range of therapeutic areas, including dermatology, women’s health, urology and others. It also has the Natroba operations and global product rights to Natroba and its authorized generic Spinosad, a topical treatment for both head lice and scabies.

TSX:CPH - Post by User

Cipher Pharmaceuticals Inc

Bullboard Posts

Post by mcdotcaon Jan 21, 2020 11:06am

139 Views

Post# 30577674

CPH Insider

I'm long on CPH (particularly for the anticipated launch of Absorbica LD this year) except I'm a little worried that despite the beating there's no insider trades. Why wouldn't Craig or anybody else be buying up more shares? Perhaps the launch is delayed much longer than we are hoping?

Bullboard Posts

What will the U.S. election results mean for Canada?